Focus Graphite Refines Roadmap for Supplying BioMedical Grade Graphite and Rare Earth Materials for Grafoid’s Roll -Out of Its Inn ovative BioMedical Applications
November 8th, 2018
For Immediate Release
FMS: TSX-VENTURE
Focus Graphite Refines Roadmap for Supplying BioMedical Grade Graphite and
Rare Earth Materials for Grafoid’s Roll -Out of Its Inn ovative BioMedical
Applications
OTTAWA – Focus Graphite Inc. (FMS: TSX -V; OTCQX: FCSMF; FSE: FKC) (“Focus” or the
“Company”) introduces its roadmap for refining BioMedical Grade Graphite to supply Grafoid’s
product line of BioMedical Applications . Already an established source of high gr ade graphite,
suitable for use in BioMedicine, Focus Graphite is also excited by the potential of its Rare Earth
projects –such as the Kwyjibo Rare Earth Element (“REE”) Project (“Kwyjibo”) – which increases
the range of materials that Focus may have the ability supply in the future.
Within biomedicine, powerful imaging techniques from the single molecule to the whole organism
directly impact the fundamental science or diagnosis. However, existing methods tend to be limited
by the optical properties of the available probes. This has motivated a growing interest in
leveraging nanoparticles for imaging – such as dye -doped silica particles, quantum dots,
nanodiamonds or metallic nanoparticles.
A highly active area of this research is focusing on the developm ent of rare -earth based
nanoparticles where optical properties and low cytotoxicity are promising for biological
applications. Rare-earth based nanoparticles offer a range of attractive properties which include
high photostability, absence of blinking, extremely narrow emission lines, large stokes shifts, long
lifetimes that can be exploited for retarded detection schemes, and facile functionalization
strategies. With such a broad range of potential benefits, REEs offer a great deal of potential for
reshaping imaging in biomedicine.
With this rapidly expanding demand for rare -earth based nanoparticles and high grade graphite
across the BioMedical spectrum, Focus Graphite is actively refining its roadmap for supplying
BioMedical grade material for Grafoid’s product pipeline. A pipeline closing in on
commercialization and recently bolstered by the addition of Dr. Shannon to Grafoid’s advisory
board. Dr. Shannon brin gs extensive experience, insight and guidance on Grafoid’s portfolio of
bio-medical applications and systems. Having received a medical degree from Queen’s University
in Canada, which included advanced training in surgery and sports medicine, Dr. Shannon a lso
holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in
applied medical research within these areas for over 27 years.
“As innovative partners – such as Grafoid – seed their pipelines for the launch of BioMedical
applications and systems– the clear advantage will be with those with access to the most reliable
supplies of high-grade source materials, such as Graphite and REEs.” said Gary Economo, CEO
of Focus Graphite, “and, as an established supplier of high-grade graphite, and an early partner
of Grafoid, we believe this synergistic relationship could represent real world potential for shaping
the BioMedicine of tomorrow.”
About Focus Graphite
Focus Graphite Inc. is an advanced exploration and mining company with an objective of
producing graphite concentrate at its wholly owned Lac Knife flake graphite deposit located 27 km
south of Fermont, Québec. In a second stage, to meet Quebec stakeholder interests of
transformation within the province and to add shareholder value. Focus is evaluating the feasibility
of producing value added graphite products including battery-grade spherical graphite.
Focus Graphite is a technology-oriented graphite mining development company with a vision for
building long-term, sustainable shareholder value. Focus also holds a significant equity position
in graphene applications developer Grafoid Inc.
For more information about Focus Graphite, please visit www.focusgraphite.com
About Grafoid.
Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that
invests in, manages and develops markets for processes that produce economically scalable
graphene for use in graphene development applications by leading corporations and institutions.
Grafoid’s leading investment produces application friendly, minimal -defect, high-energy density
few layer graphene, utilizing a safe, non -destructive extraction process, leaving the lowest
possible ecological footprint. The completely unique, proprietary process results in what Grafoid
regards as a new global standard for economically scalable, high -purity graphene products —
trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and
commercial applications.
Contact:
Focus Graphite Inc.
Mr. Gary Economo
Chief Executive Officer
+1-613-241-4040
www.focusgraphite.com